secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001193125-26-001098
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02, 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics terminates TRA, adopts governance changes reducing Class B voting to 1 vote
--------------------------------------------------------------------------------

- Terminated Tax Receivable Agreement with InCube Labs; no payments or early termination fees required.
- Amended charter reduces Class B common stock voting power from 10 to 1 vote per share.
- Eliminated stockholder written consent, classified board; added supermajority vote to amend bylaws.
- Changes approved by majority holder written consent on Nov 24, 2025; effective Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/0001193125-26-001098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/d848686d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer